Key result
Natriuretic peptides serve as valuable diagnostic and prognostic biomarkers in acute dyspnea, HF, and CAD.
Review demonstrates the role of natriuretic peptides in fluid homeostasis, highlighting their value as biomarkers and therapeutic targets in heart failure.
Natriuretic peptides (NPs) are released from the heart in response to pressure and volume overload. B-type natriuretic peptide (BNP) and N-terminal-proBNP have become important diagnostic tools for assessing patients who present acutely with dyspnea. The NP level reflects a compilation of systolic and diastolic function as well as right ventricular and valvular function. Studies suggest that using NPs in the emergency department can reduce the consumption of hospital resources and can lower costs by either eliminating the need for other, more expensive tests or by establishing an alternative diagnosis that does not require hospital stay. Caveats such as body mass index and renal function must be taken into account when analyzing NP levels. Natriuretic peptide levels have important prognostic value in multiple clinical settings, including in patients with stable coronary artery disease and with acute coronary syndromes. In patients with decompensated heart failure due to volume overload, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels. Knowing a patient's NP levels might thus assist with hemodynamic assessment and subsequent treatment titration. Monitoring NP levels in the outpatient setting might also improve patient care and outcomes.
No takes yet. Share an insight, caveat, or question.
Daniels et al. (2007) conducted a review in Dyspnea and Heart Failure. Natriuretic peptides (BNP and NT-proBNP) was evaluated. Natriuretic peptides serve as valuable diagnostic and prognostic biomarkers for patients presenting with acute dyspnea, heart failure, and coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: